523144 MEDICAPQ

MediCaps Share Price

 

 

Start SIP in MEDICAPQ

Start SIP

Performance

  • Low
  • ₹23
  • High
  • ₹26
  • 52 Week Low
  • ₹21
  • 52 Week High
  • ₹54
  • Open Price₹26
  • Previous Close₹25
  • Volume32,888
  • 50 DMA₹28.46
  • 100 DMA₹31.86
  • 200 DMA₹36.08

Investment Returns

  • Over 1 Month -22.24%
  • Over 3 Month -35.63%
  • Over 6 Month -40.18%
  • Over 1 Year -46.19%

Smart Investing Starts Here Start SIP with MediCaps for Steady Growth!

Invest Now

MediCaps Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -6.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 30
  • P/B Ratio
  • 0.3
  • Average True Range
  • 2.43
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.87
  • RSI
  • 38.75
  • MFI
  • 44.31

MediCaps Financials

MediCaps Technicals

EMA & SMA

Current Price
₹23.67
-1.42 (-5.66%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹25.31
  • 50 Day
  • ₹28.46
  • 100 Day
  • ₹31.86
  • 200 Day
  • ₹36.08

Resistance and Support

24.08 Pivot Speed
  • R3 29.08
  • R2 27.51
  • R1 25.65
  • S1 22.22
  • S2 20.65
  • S3 18.79

MediCaps Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-11 Quarterly Results
2025-11-12 Quarterly Results
2025-08-05 Quarterly Results
2025-05-21 Audited Results
2025-02-12 Quarterly Results

MediCaps F&O

MediCaps Shareholding Pattern

50.76%
0%
0.02%
44.43%
4.79%

MediCaps FAQs

MediCaps share price is ₹23 As on 20 February, 2026 | 04:21

The Market Cap of MediCaps is ₹29.5 Cr As on 20 February, 2026 | 04:21

The P/E ratio of MediCaps is -6.8 As on 20 February, 2026 | 04:21

The PB ratio of MediCaps is 0.3 As on 20 February, 2026 | 04:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23